Home » Stocks » Menlo Therapeutics

Menlo Therapeutics Inc. (MNLO)

Sep 8, 2020 - Stock symbol was changed to VYNE

Stock Price: $1.35 USD 0.00 (0.00%)

Updated Sep 4, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap	226.38M
Revenue (ttm)	13.44M
Net Income (ttm)	-246.03M
Shares Out	167.69M
EPS (ttm)	-5.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Dividend Yield	n/a

Stock Quote

Trading Day	Sep 4, 2020
Last Price	$1.35
Previous Close	$1.35
Change ($)	0.00
Change (%)	0.00%
Day's Open	-
Day's Range	1.30 - 1.39
Day's Volume	0
52-Week Range	1.00 - 7.48

More Stats

Market Cap	226.38M
Enterprise Value	161.44M
Earnings Date (est)	n/a
Ex-Dividend Date	n/a
Shares Outstanding	167.69M
Float	159.36M
EPS (basic)	-3.75
EPS (diluted)	-5.01
FCF / Share	-0.87

Dividend	n/a
Dividend Yield	n/a
Earnings Yield	n/a
FCF Yield	n/a
Payout Ratio	n/a
Shares Short	11.24M
Short Ratio	4.59
Short % of Float	7.05%
Beta	1.69

PE Ratio	n/a
Forward PE	n/a
P/FCF Ratio	n/a
PS Ratio	16.85
PB Ratio	3.35
Revenue	13.44M
Operating Income	-246.42M
Net Income	-246.03M
Free Cash Flow	-120.98M

Net Cash	64.94M
Net Cash / Share	0.39
Gross Margin	3.26%
Operating Margin	-1,833.77%
Profit Margin	-1,830.80%
FCF Margin	-900.25%
ROA	-68.11%
ROE	-407.33%
ROIC	-453.60%

Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (8)

Buy	8
Overweight	0
Hold	0
Underweight	0
Sell	0

What these ratings mean

Analyst Consensus: Buy

Price Target

$6.62*

(390.37% upside)

Low

3.00

Current: $1.35

High

15.00

Target: 6.62

*Average 12-month price target from 8 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year	2019	2018	2017	2016	2015
Revenue	-	10.64	4.58	0.67	-
Revenue Growth	-	132.21%	579.82%	-	-
Gross Profit	-	10.64	4.58	0.67	-
Operating Income	-76.24	-54.54	-29.59	-14.33	-4.61
Net Income	-73.70	-51.45	-29.08	-14.07	-4.61
Shares Outstanding	23.82	21.67	5.11	4.99	4.74
Earnings Per Share	-3.09	-2.37	-5.69	-2.82	-0.97
Operating Cash Flow	-65.10	-52.73	-28.22	-2.27	-4.18
Capital Expenditures	-0.01	-0.14	-0.03	-0.03	-
Free Cash Flow	-65.11	-52.87	-28.25	-2.30	-4.18
Cash & Equivalents	73.37	136	59.50	30.91	43.81
Total Debt	34.47	-	-	-	-
Net Cash / Debt	38.90	136	59.50	30.91	43.81
Assets	81.16	140	66.87	42.05	43.89
Liabilities	63.58	9.55	14.57	12.49	0.84
Book Value	17.58	130	-57.03	-29.44	-15.95

Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name	Menlo Therapeutics Inc.
Country	United States
CEO	David Domzalski

Stock Information

Ticker Symbol	MNLO
Stock Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology
Unique Identifier	NASDAQ: MNLO
IPO Date	January 25, 2018

Description

Menlo Therapeutics, a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was founded in 2003 and is headquartered in Bridgewater, New Jersey.